hospitalization, the need for hemodialysis arose and dialysis was applied 4 times. The follow-up laboratory test results were BUN: 31 mg/dL, serum creatinine: 1.2 mg/dL, AST: 19 U/L, ALT: 38 U/L, CK: 284 U/L, Na: 141 mmol/L, K 3.4 mmol/L, P 3.4 mg/dL. Polyuria developed but decreased during the follow-up and renal function tests returned to normal levels. When an improvement was determined in the general symptoms and laboratory findings, the patient was discharged with a treatment plan and an outpatient clinic follow-up examination for 10 days later.
Discussion
Statins are widely used in the treatment of HL and they are usually safe drugs. However, findings ranging from non-specific symptoms such as myalgia and muscle weakness to rhabdomyolysis-induced ARF can be seen in patients taking statins. This situation is associated with elevation of CK. Clinical symptoms and serum CK levels improve quickly after discontinuation of the drug. The risk of developing statin-associated myalgia has been reported as 2%-11%, risk of myositis at 0.5%, and the risk of rhabdomyolysis at approximately 0.1% (2). Rhabdomyolysis is defined as a severe myopathy with muscle symptoms and elevation of CK more than ten times the upper limit of normal (3) . Clinical signs of rhabdomyolysis include pain in the muscles, tenderness, skin discoloration in the affected regions, pain mostly in the waist and thigh, fatigue, tachycardia, nausea and vomiting, fever, and palpitations (4). The most common presentation of rhabdomyolysis is muscle weakness, pain, cramps and edema with tea colored (red-brown) urine (5) . ARF occurs in approximately 30% of rhabdomyolysis cases. Rhabdomyolysis is the cause in 8% of all cases of ARF. Rhabdomyolysis-induced ARF is caused by hypovolemia related to rhabdomyolysis or the direct toxic effect of myoglobin if there is no underlying cause (6). In the current case, the patient had been taking additional treatment without medical advice and statin-induced rhabdomyolysis and ARF developed. In conclusion, statins are in current widespread use and because of the potential fatal side effects, these medications should be chosen carefully. These drugs must be used for the correct indications and at the right dose and there should be regular monitoring of kidney and liver functions and muscle enzymes. Patients must be evaluated for rhabdomyolysis facilitating factors, and they should be informed about the side effects and symptoms of myopathy.
Ethical issues
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